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PMesenchymal Stem Cells Provide Better
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Ana Armiña´n, PHD,*† Carolina Gandı´a, PHD,*† J. Manuel Garcı´a-Verdugo, PHD,†‡
Elisa Lledo´, PHD,*† César Trigueros, PHD,§ Amparo Ruiz-Saurı´, MD, PHD,‡
Marı´a Dolores Miñana, PHD, Pilar Solves, MD, PHD,¶ Rafael Paya´, MD, PHD,
J. Anastasio Montero, MD, PHD,*† Pilar Sepúlveda, PHD*†
Valencia and San Sebastián, Spain
Objectives The purpose of this study was to compare the ability of human CD34 hematopoietic stem cells and bone mar-
row mesenchymal stem cells (MSC) to treat myocardial infarction (MI) in a model of permanent left descendent
coronary artery (LDA) ligation in nude rats.
Background Transplantation of human CD34 cells and MSC has been proved to be effective in treating MI, but no compara-
tive studies have been performed to elucidate which treatment prevents left ventricular (LV) remodelling more
efficiently.
Methods Human bone marrow MSC or freshly isolated CD34 cells from umbilical cord blood were injected intramyocar-
dially in infarcted nude rats. Cardiac function was analyzed by echocardiography. Ventricular remodelling was
evaluated by tissue histology and electron microscopy, and neo-formed vessels were quantified by immunohisto-
chemistry. Chronic local inflammatory infiltrates were evaluated in LV wall by hematoxylin-eosin staining. Apop-
tosis of infarcted tissue was evaluated by terminal deoxynucleotidyl transferase dUTP nick end labeling assay.
Results Both cell types induced an improvement in LV cardiac function and increased tissue cell proliferation in myocar-
dial tissue and neoangiogenesis. However, MSC were more effective for the reduction of infarct size and preven-
tion of ventricular remodelling. Scar tissue was 17.48  1.29% in the CD34 group and 10.36  1.07% in the
MSC group (p  0.001 in MSC vs. CD34). Moreover, unlike MSC, CD34-treated animals showed local inflam-
matory infiltrates in LV wall that persisted 4 weeks after transplantation.
Conclusions Mesenchymal stem cells might be more effective than CD34 cells for the healing of the infarct. This study con-
tributes to elucidate the mechanisms by which these cell types operate in the course of MI treatment. (J Am
Coll Cardiol 2010;55:2244–53) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.092a
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iyocardial infarction (MI) is still one of the main causes of
ortality and morbidity in developed countries. In the acute
etting, approaches to improve myocardial perfusion range
rom pharmacological therapies (thrombolysis) to mechan-
cal procedures (primary angioplasty). Recently, several stem
ell types have been used in small and large clinical trials in
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ccepted August 10, 2009.djunction to conventional therapies for the treatment of
I. First studies of cellular angioplasty were held with bone
arrow mononuclear cells (1), and to date all clinical trials
ave reported similar results, with approximately 8% im-
rovement in global left ventricular (LV) fraction, reduced
nd-systolic volumes, and improved perfusion in the in-
arcted area 4 to 6 months after cell transplantation (2,3).
See page 2254
hese clinical trials were followed by others with cellular
amples enriched for cell progenitors, like circulating
lood progenitor cells (2,4) or bone marrow mesenchymal
tem cells (MSC) (5,6). However, the enormous variabil-
ty in the technical procedures used in each study made
omparison difficult. For this reason, studies using dif-
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orward.
In this study, we designed a set of experiments to
ompare, head-to-head, the ability of 2 human adult stem
ell populations—CD34 cells and MSC—to repair MI.
hese cell types have become the most clinically relevant
or cardiovascular cell therapies. Thus, the data presented
ere could be useful for the design of more efficient
linical trials with less collateral effects.
ethods
ll procedures were approved by the Instituto de Salud
arlos III and institutional ethical and animal care
ommittees.
Figure 1 Characterization of Human CD34-Umbilical Cord
Blood Cells and Bone Marrow MSC
(A) Cell sorting of umbilical cord blood mononuclear fraction with the MACS
system (Miltenyi, Bergisch, Germany) and labeling of freshly isolated CD34
cells with the vital marker DiI (Molecular Probes, Invitrogen, Eugene, Oregon).
Isolated CD34 cells were photographed at 160 magnification. (B) Mesen-
chymal stem cells (MSC) in culture (magnification 200). Retroviral labeling of
cultured MSC yielded 95% infection as detected by flow cytometric analysis of
green fluorescent protein (GFP)-MSC. Representative flow cytometric analysis of
antigenic expression is shown. Shaded histograms represent staining with spe-
cific antibodies, and open histograms correspond to matched isotypes. FSC 
forward scatter; SSC  side scatter.lells, culture conditions, and
etroviral labeling. Human bone
arrow MSC (n  3) (Inbiomed,
an Sebastian, Guipuzcoa, Spain)
ere cultured following the man-
facturers’ instructions and retro-
irally labeled with green fluores-
ent protein as previously reported
7). Transduction efficiency was
valuated by flow cytometry. The
D34 human umbilical cord
lood cells (n  14) were isolated
ith the autoMACS system (Milte-
yi, Bergisch, Germany) as previ-
usly reported (8). For some exper-
ments CD34 cells were labeled
ith the vital marker CM-Di I,
ollowing the manufacturers’ in-
tructions (Molecular Probes, In-
itrogen, Eugene, Oregon).
nimals. Nude rats weighing 200 to 250 g (HIH-Foxn1
nu, Charles River Laboratories, Inc., Wilmington, Massa-
husetts) were used. The initial number of animals included
n the study was 90. Animals with fractional shortening
FS) above 35% after MI were excluded. Mortality in all
roups due to surgical procedures was approximately 30%.
I and cell transplantation. Permanent ligation of the
eft coronary artery was performed as previously described
7,9). Seven days later, rats were anesthetized with sevoflu-
ane inhalatory anesthesia (2.5% v/v) followed by IP injec-
ion of fentanyl (0.05 mg/kg) and re-opened by a midline
ternotomy to perform intramyocardical transplantation (sa-
ine, 6  105 CD34 cells or 1.2  106 MSC/animal in 5
njections of 5-l volume, at 5 points of the infarct border
one with a Hamilton syringe).
-bromodeoxyuridine treatment and analysis of proliferating
ells. After cell transplantation, each animal was given
aily 0.5-ml IP injection of 5-bromodeoxyuridine (BrdU)
50 mg/kg body weight, IP) for 2 weeks. The BrdU was
lso given orally in tap water (1 mg/ml) (10). The
rdU-labeled cells in heart tissue were identified with an
nti-BrdU antibody (Abcam, Cambridge, Massachu-
etts). Proliferation index was calculated as a percentage
f BrdU-labeled nuclei/total of nuclei identified by 4’-6-
iamidino-2-phentanyl staining. Identification of prolif-
rating myofibroblasts or cardiomyocytes was performed
y double staining with anti-BrdU antibodies and anti-
mooth muscle actin (SMA) or anti-troponin I, respec-
ively (both antibodies from Chemicon International,
arrow, United Kingdom). One thousand SMA cells
r troponin I cells were counted. The SMA cells
ncorporated into vessel structures were not included in
he counting.
unctional assessment by echocardiography. Transtho-
acic echocardiography was performed in rats under inha-
Abbreviations
and Acronyms
AW  anterior wall
thickness
BrdU  5-bromodeoxyuridine
EDA  end-diastolic area
ESA  end-systolic area
FAC  fractional area
change
FS  fractional shortening
LV  left ventricular
MI  myocardial infarction
MSC  mesenchymal stem
cells
PW  posterior wall
thickness
SMA  smooth muscle
actinatory anesthesia (Sevoflurane) with an echocardiographic
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Adult Stem Cells for Myocardial Repair May 18, 2010:2244–53ystem (General Electric, Waukesha, Wisconsin) equipped
ith a 10-MHz linear-array transducer as previously re-
orted (7). Measurements were taken at baseline, after
nfarction, and after transplantation (2 weeks and 4 weeks).
eft ventricular dimensions in end-diastole (LVDd) and
nd-systole (LVDs), anterior wall (AW) and posterior wall
hickness in diastole and systole, end-diastolic area (EDA),
nd end-systolic area (ESA) were measured. Changes in
W were calculated as: (AWs  AWd/AWd)  100. The
S was calculated as: ([LVDd  LVDs]/LVDd)  100.
ractional area change (FAC) was calculated as: ([EDA–
SA]/EDA)  100.
mmunohistochemistry and electron microscopy. Four
eeks after implantation, animals were killed, and the hearts
ere removed and washed with phosphate-buffered saline
nd fixed in 2% paraformaldehyde or 2% paraformaldehyde/
lutaraldehyde for electron microscopy examination. Heart
issue sections were prepared for immunohistochemistry as
reviously reported (7). For electron microscopy analysis,
emi-thin (1.5 m) and ultrathin (0.05 m) sections were
repared (7). Muscular and fibrotic layer thickness at the
nfarct border were calculated in transmural LV wall semi-
hin sections (n 5 animals in each group), and values were
Figure 2 Measurement of LV Function in
Saline-, CD34-, or MSC-Treated Animals
Measurement of left ventricular (LV) function in saline-treated (n  15), CD34-
treated (n  11), or mesenchymal stem cells (MSC)-treated (n  14) animals.
Quantified values of fractional shortening (FS), fractional area change (FAC),
and anterior wall thickening (AWT) are given. Saline group (solid bars), CD34
group (ruled bars), and MSC group (open bars). *p  0.05; †p  0.01;
‡p  0.001. MI  myocardial infarction.Ec
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May 18, 2010:2244–53 Adult Stem Cells for Myocardial Repairxpressed as a percentage of the total LV wall thickness.
ellular infiltrates were identified on heart tissue after
taining of paraffin-embedded sections with hematoxylin/
osin solution (Merk, Darmstsdt, Germany).
ascular density analysis. Immunohistochemical detec-
ion of vessels was performed with anti-rat CD31 (Chemi-
on International). Vessels were counted in 10 fields in the
eri-infarct zone at 200 and referred as number of
Figure 3 Effect of Cell Transplantation on Infarct Size
(A) Representative heart sections from infarcted nude rats receiving saline, CD34
lated in Masson’s Trychrome stained sections. Arrows point to the border zones o
tation. Representative sections and quantification of the total number of vessels iessels/unit area (mm2) with a light microscope and the amage Pro-Plus 5.1 software (Media Cybernetics, Inc.,
ethesda, Maryland).
orphometry. The infarct size in the LV was measured in 8
o 12 transverse sections of 14 m (1 slice each 200 m of
issue) from apex to base, fixed with 2% paraformaldehyde, and
tained with Masson’s trichrome. The fibrotic zone was deter-
ined by computer planimetry (Image Pro-Plus 5.1 software,
edia Cybernetics, Inc.). Infarct size was expressed as percent-
, or mesenchymal stem cells (MSC). Fibrotic area in the left ventricle was calcu-
nfarct. (B) Neovascularization in the border infarct, 4 weeks after cell transplan-
roups (n  6 in each group). *p  0.05; ‡p  0.001. cells
f the i
n all gge of total LV area and as a mean of all slices from each heart.
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Adult Stem Cells for Myocardial Repair May 18, 2010:2244–53erminal deoxynucleotidyl transferase dUTP nick end
abeling assay. Apoptotic cells in heart tissue were detected
ith the ApopTagPlus Fluorescein In situ Apoptosis De-
ection Kit (Chemicon International) following the manu-
acturers’ instructions.
tatistical analysis. Data are expressed as mean  SEM.
ll statistical analyses were performed with the SPSS
oftware, version 14.0 (SPSS, Chicago, Illinois). Compari-
ons between MI and 4 weeks after transplantation in each
roup were performed with a Wilcoxon W test. Pairwise
omparisons between groups at different time points were
one with a Mann-Whitney U test. Differences were
onsidered statistically significant at p  0.05 with a 95%
onfidence interval.
esults
SC and CD34 cells isolation, characterization, and
abeling. Purified CD34 cells were labeled with CM-Di I
Molecular Probes), washed, and used for some in vivo
tudies. Percentage of labeled cells was more than 99.5%
Fig. 1A). Human bone marrow MSC were expanded,
haracterized, and labeled with green fluorescent protein by
etroviral transduction (Fig. 1B). The percentage of infec-
ion was 90  5%. The MSC phenotype was maintained
fter retroviral labeling as determined by fluorescein-
ctivated cell sorting analysis (Fig. 1B).
ell transplantation and LV function. Seven days after
I, 6  105 CD34 cells or 1.2  106 MSC were injected
ntramyocardially. The optimal doses to induce improvement
n cardiac function were selected on the basis of previous
tudies performed by our group and others (7,11). Because
D34 cells display a higher proliferative capacity in vitro and
n vivo, we inoculated half dose with respect to MSC. Fur-
hermore, the dose used for CD34 cells was sufficient to
mprove cardiac function as described (11). The echocardio-
raphic parameters from all groups are listed in Table 1.
hanges were monitored at baseline, after MI, and after
ransplantation (2 and 4 weeks). At baseline and after MI, the
alues of the echocardiographic parameters analyzed were
imilar among the 3 groups, indicating comparable levels of
issue injury. In cell-treated groups, the improvement in
ardiac performance in terms of FS and FAC was observed 2
eeks after transplantation and maintained at least 2 more
eeks (Fig. 2). Indeed, 4 weeks after transplantation, FAC was
8.00  2.64% in saline, 48.89  2.41% in the CD34 group,
nd 49.25 2.16% in the MSC group (p 0.01 in CD34 and
SC vs. saline). At this time point, FS was 26.00 1.76% in
aline, 32.17 1.62% in the CD34 group, and 32.07 1.53%
n the MSC group (p  0.05 in CD34 and MSC vs. saline).
he AW thickening was significantly higher in animals trans-
lanted with MSC (28.22  3.27% in saline, 32.99  4.83%
n the CD34 group, and 41.35  3.90% in the MSC group;
 0.05 in MSC vs. saline at 4 weeks), indicating that MSCere more effective in preventing wall thinning and remodel-
ng than CD34 cells (Fig. 2).
all thickness and angiogenesis in CD34 and MSC
ransplanted animals. Quantification of infarct area in ani-
als from each group revealed that only the MSC group
howed a reduced area of fibrous scar tissue (Fig. 3A).
ercentage of scar tissue was 18.49  1.58% in the saline
roup, 17.48 1.29% in the CD34 group, and 10.36 1.07%
n the MSC group (p 0.001 in MSC vs. saline and CD34).
apillary density in the LV wall was significantly greater in the
D34 and MSC groups than in the saline group, as assessed
8 days after implantation (Fig. 3B). Number of vessels/mm2
ere 567  63 in the saline group, 818  41 in the CD34
roup, and 781  35 in the MSC group (p  0.05 in CD34
s. saline and MSC vs. saline), confirming the strong ability of
SC and CD34 cells to induce neoangiogenesis.
rganization of the infarcted tissue in CD34 and MSC
roups. Analysis of ultrathin sections from infarct border
issue revealed the marked thinning of ventricular wall in
he saline group, due to the fibrotic scar maturation, 4 weeks
fter treatment (Fig. 4). In contrast, in the CD34 and MSC
Figure 4 Organization of Cardiac
Tissue at the Peri-Infarct Zone
Representative ultra-thin sections of left ventricular walls at the peri-infarct
zone from a control-, CD34-, or mesenchymal stem cells (MSC)-transplanted
animal, 4 weeks after transplantation. Contiguous electron micrographs were
assembled into a photomontage. The contours of the different cell types were
traced in different colors. Scale bar  5 m.
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nd subendocardium cardiomyocyte layers at the same time
oint. Moreover, the MSC group showed additional bands
f myocardial tissue disposed between the fibrotic layers,
esulting in further increase of LV wall thickness. Cardio-
yocyte muscle layers at the infarct border constituted
5.16  7.23% of the total LV wall thickness in the saline
roup, 48.41  7.59% in the CD34 group, and 71.0 
.39% in the MSC group (p  0.05 in MSC vs. CD34 and
Figure 5 Localization of CD34 or MSC-Transplanted Cells in the
(A) Heart sections of CD34- and MSC-transplanted animals, respectively. Areas in
visualize human transplanted cells, in CD34-transplanted animals, cells were labe
actin (SMA) antibodies, whereas in MSC-treated animals, MSC retrovirally labeled
with anti-SMA antibodies. (B) Immunohistochemistry of infarcted heart sections fro
SMA (red) and anti-collagen I (green). (D) Myofibroblast rim detection by electron
detail of a fibroblast. *Myofiber bundles along the cell axis. Arrows show vesicles
100 magnification). Other abbreviations as in Figure 1.s. saline). A comparison between MSC and CD34 cells nigratory capacity in ischemic tissue showed that most
D34 cells were retained at the site of injection, whereas
SC migrate from the site of implantation to the infarcted
one and were placed in the intermediate fibrotic rim
etween subepicardium and subendocardium (n  4)
Fig. 5A). Interestingly, in this layer we observed differences in
nfarcted tissue organization among groups. The MSC group
howed an increase in myofibroblast, as detected by anti-SMA.
his myofibroblast layer was thinner in the CD34 group and
der and Infarct Zone
in the squares are shown at higher magnification on the left of the figure. To
h DiI (red) and fibrotic tissue was stained in green with anti-smooth muscle
FP were visualized by the green epifluorescence, and tissue was labeled in red
erent groups with anti-rat SMA antibodies. (C) Double immunostaining with anti-
copy. (E) Detail of myofiber organization in a myofibroblast. (F) Ultrastructural
cytosis. Scale bar  100 m in A, 5 m in D, and 0.5 m in E and F. (B, C Bor
cluded
led wit
with G
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micros
of exoearly absent in the saline group (Fig 5B). On the contrary,
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Adult Stem Cells for Myocardial Repair May 18, 2010:2244–53xpression of collagen I at the infarct zone was reduced in the
SC group but not in the CD34 group (Fig. 5C), indicating
he influence of MSC transplantation in extracellular matrix
eorganization. Because there is paucity in antibodies able to
istinguish myofibroblasts from fibroblasts, electron micros-
opy analysis was performed to further characterize the
broblast/myofibroblasts rim (Fig. 5D). Although iden-
ical in size, shape, and cytoplasmic structure, myofibro-
lasts were distinguished from fibroblasts by the presence of
bundant myofilaments along the cellular axis (Figs. 5E and
F). The fact that the MSC group showed increased
Figure 6 Analysis of Tissue Regeneration in Stem Cell-Treated
(A) Total number of 5-bromodeoxyuridine (BrdU) cells. (B) Percentage of apopto
assay. (C, D) Percentage of proliferating smooth muscle actin (SMA) cells and cardi
anti-Troponin (Tn) I (green) antibodies, respectively. Representative images of double
m. Results are expressed as mean  SEM (%) (n  5 in each group). *p  0.05; †yofibroblast accumulation and decreased collagen deposi-
ion correlated with morphometric studies and pointed to
he superior ability of MSC to inverse LV remodelling.
issue regeneration in stem cell-treated animals. To
nvestigate whether anterior wall thickening and decrease
f infarct size was associated with cell proliferation in
nfarcted tissue, we quantified the number of BrdU cells
n the LV of BrdU-treated animals (n  5 in each group).
he results showed that MSC induced the highest cell
roliferation in myocardial tissue (proliferation index was
2.3  1.5% in the saline group, 17.3  2.5% in the
als
s assessed by terminal deoxynucleotidyl transferase dUTP nick end labeling
ytes, as detected by double staining with anti-BrdU (pink) and anti-SMA (green) or
g are shown. Nuclei were stained with 4’-6-diamidino-2-phenylindole. Scale bar  5
01; ‡p  0.001.Anim
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.05 in MSC vs. saline) (Fig. 6A). In addition, the
umber of apoptotic cells in the border zone of animals
ransplanted with MSC was lower than in the other
roups (14.43  1.87 in the saline group, 3.20  0.40 in
he CD34 group, and 1.20  0.30 in the MSC group; p 
.01 in CD34 vs. saline and MSC vs. saline) (Fig. 6B). A
ore exhaustive analysis revealed that most BrdU cells
howed a fibroblastic morphology and were positively
tained with anti-rat SMA antibodies (proliferation index
f SMA cells was 12.93  1.64% in the control group,
3.81  1.53% in the CD34 group, and 27.36  2.88%
n the MSC group; p  0.05 in CD34 vs. saline and p 
.01 in MSC vs. saline) (Fig. 6C). Interestingly, troponin
staining revealed the presence of proliferating cardio-
yocytes (cardiomyocyte proliferation index was 0.42 
.28% in the control group, 1.49  0.20% in the CD34
roup, and 1.59  0.18% in the MSC group; p  0.05 in
D34 vs. saline and MSC vs. saline) (Fig. 6D). These
Figure 7 Analysis of Cell Infiltration in Stem Cell-Treated Anima
(A) Quantification of infiltrating cells in saline-, CD34-, and mesenchymal stem cel
or intense. (B) Detail of epicardial tissue in representative sections of saline, CD3roliferating cells were not from human origin, because
hey were not stained with anti-human nuclei antibodies
not shown). Thus they might be a consequence of
aracrine effects exerted by transplanted cells.
ollateral effects induced by stem cell transplantation. It
s known that cell transplantation promotes interstitial
ononuclear cell infiltration shortly after infusion. How-
ver, CD34-treated animals showed higher levels of cell
nfiltration in comparison with MSC transplanted animals
t the latest time points (Fig. 7A). This effect was markedly
atent in the epicardial tissue where animals from the CD34
roup showed dramatic cell infiltration in comparison with
SC and saline groups (Fig. 7B).
iscussion
dult stem cell transplantation is an adjuvant treatment to
onventional therapies of cardiac ischemic injury. However,
he best cell type for each therapeutic application remains to
e determined, and more preclinical studies should be
C)-treated animals classified as slight, moderate,
MSC transplanted animals (100 magnification).ls
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Adult Stem Cells for Myocardial Repair May 18, 2010:2244–53erformed to define the most suitable cell type to be used in
he clinical practice (3,12,13).
In this study we demonstrate that MSC transplanta-
ion prevents ventricular remodelling and exerts fewer
ollateral effects than CD34 cell transplantation. We
id not find significant differences in ventricular perfor-
ance between MSC and CD34 groups in terms of FS
nd FAC at 2 or 4 weeks after transplantation. However,
chocardiographic parameters related to wall thickening and
orphometric/histological studies clearly showed that MSC
ransplantation prevented the thinning of the LV wall and
ecreased infarct size more efficiently than CD34 cell
ransplantation. The higher sensibility of histological and
lectron microscopy versus echocardiography to evaluate
yocardial architecture and heart geometry in small animals
ould explain these discrepancies.
General consensus supports the paracrine hypothesis to
xplain cardiac repair (14 –16). The superior ability of
SC to migrate from the site of injection to the infarcted
one, in comparison with CD34 cells, could help them
o exert their paracrine effect. Indeed, hypoxia or inflam-
atory mediators in the ischemic niche could be respon-
ible for MSC migration. For instance, hypoxia induces
XCR4 upregulation via hypoxia inducible factor-1-
lpha (17), and a recent work shows that stromal cell-
erived factor-1-alpha/CXCR4 interaction is involved in
he retention of MSC in the ischemic heart (18). In a
imilar way, tumor necrosis factor-alpha pre-treatment or
verexpression enhances MSC engraftment in cardiac
issue and improves recovery of cardiac function after MI
13,19).
Other phenomena could explain the differences in the
ound-healing process observed among groups. MSC
ransplantation favors myofibroblast proliferation as ob-
erved in BrdU experiments. In addition, the myofibro-
last middle layer was thicker in animals transplanted
ith both stem cell types than in the saline group but
ore markedly in the MSC group, as detected by
mmunohistochemistry with anti-SMA antibodies.
yofibroblasts confer elasticity and contractility to the
V wall and improve wall motion and healing (20,21).
fter MI, myofibroblasts proliferate to promote infarct
ealing but die a few days later when the scar is generated
n the infarcted region (22). Thus, therapies capable of
ctivating this cell type would be beneficial in the wound
epair (22,23).
Another important observation is the ability of MSC to
educe collagen I deposition at the infarct zone. Although
e could not quantify it, previous works have shown the
nfluence of MSC transplantation in attenuation of fibrosis
nd collagen I deposition (24–26).
onclusions
e have demonstrated that CD34 cells—their therapeutic
otential notwithstanding—induce a chronic cell infiltrationf cardiac tissue and do not efficiently prevent LV remod-
lling. Mesenchymal stem cells, however, migrate to the site
f infarction, potentiate the healing of the infarct, and
ontrol the remodelling process. Thus, the latter seems to be
ore appropriate to use in clinical practice for the treatment
f MI.
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